CVOT Summit Report 2025: advances along the cardiovascular-kidney-metabolic disease continuum.

Oliver Schnell, Arnav Agarwal, Michel Azizi, Dennis Ballwieser, Katharine Barnard-Kelly, Tadej Battelino, Dennis Ballwieser, Matthias Blüher, Elisabetta Bugianesi, Ana Cebrian, Antonio Ceriello, Pratik Choudhary, Thomas Danne, Colin M Dayan, Stefano Del Prato, Robert H Eckel, Paola Fioretto, Timothy Garvey, Jennifer B Green, Hiddo J L Heerspink, Rury R Holman, Baruch Itzhak, Stephan Jacob, Pardeep S Jhund, Linong Ji, Parminder K Judge, Kamlesh Khunti, Marko Korenjak, Andrew J Krentz, Ekaterini Lambrinou, Peter Libby, Julia K Mader, Johannes F E Mann, Nikolaus Marx, Chantal Mathieu, John J V McMurray, Dirk Müller-Wieland, Nikolaos Papanas, Dipesh C Patel, Andreas F H Pfeiffer, Susanne Reger-Tan, Helena W Rodbard, Giuseppe M C Rosano, Banshi Saboo, Naoki Sato, Scott D Solomon, Eberhard Standl, Frank Tacke, Pinar Topsever, Christoph Wanner, Sean Wharton, Veronika Young

Journal: Cardiovascular diabetology 2026;25(1):

PMID: 42092956

Abstract

The 11th Cardiovascular Outcome Trial (CVOT) Summit: Congress on Cardiovascular, Kidney, and Metabolic Outcomes was held virtually on November 20-21, 2025. The Summit provided a multidisciplinary forum to review and discuss recent outcome trials investigating emerging pharmacological therapies targeting diseases of the cardiovascular-kidney-metabolic (CKM) continuum. This report highlights the unique developments of 2025 discussed during the Summit, including the first head-to-head CVOT (SURPASS-CVOT), the growing evidence base for combination therapies across the disease spectrum, new insights into the inflammatory component of the CKM syndrome, and relevant policy developments. The first part of this report summarizes pioneering clinical trials addressing combination therapy with finerenone and empagliflozin (CONFIDENCE), the oral glucagon-like peptide-1 (GLP-1) receptor agonists orforglipron (ATTAIN-1), and the aldosterone synthase inhibitor (ASI) baxdrostat (BaxHTN). The second part presents recent guideline and policy developments discussed by experts in endocrinology, diabetology, cardiology, nephrology, hepatology, and general practice. In addition, advances in medical technology, particularly in continuous glucose and ketone monitoring, are highlighted, as well as emerging therapies for diseases of the CKM continuum. These include pharmacological agents for a broad spectrum of metabolic disorders such as metabolic liver disease and type 1 Diabetes (T1D) alongside emphasis on the importance of early detection and innovative treatment strategies. The 12th Cardiovascular Outcome Trial Summit will be held virtually on 19-20 November 2026 ( http://www.cvot.org ).

© 2026. The Author(s).

Address: Forschergruppe Diabetes E. V., Helmholtz Center Munich, Ingolstaedter Landstraße 1, 85764, Neuherberg, Germany. [email protected].; Division of General Internal Medicine, Department of Medicine, University of Alberta, Edmonton, AB, Canada.; Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada.; MAGIC Evidence Ecosystem Foundation, Oslo, Norway.; Université Paris Cité, INSERM Centre d'Investigation Clinique 1418, Paris, France.; Department of Hypertension, Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Paris, France.; Wort & Bild Verlag, Baierbrunn, Germany.; Southern Health NHS Foundation Trust, Southampton, UK.; University Medical Center, Ljubljana, Slovenia.; Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.; Helmholtz Institute for Metabolic, Obesity, and Vascular Research (HI-MAG), Leipzig, Germany.; Faculty of Medicine, University of Leipzig, Leipzig, Germany.; Department of Medical Sciences, University of Turin, Turin, Italy.; Cartagena Casco Health Center, 30201, Murcia, Spain.; Murcian Institute for Biosanitary Research (IMIB), Murcia, Spain.; IRCCS MultiMedica, Milan, Italy.; Diabetes Research Centre, College of Life Sciences, University of Leicester, Leicester, UK.; NOVA Medical School, Lisbon, Portugal.; Cardiff University School of Medicine, Cardiff, UK.; Interdisciplinary Research Center "Health Science", Sant'Anna School of Advanced Studies, Pisa, Italy.; University of Colorado Anschutz Medical Campus, Aurora, CO, USA.; Faculty of Medicine, University of Padova, Padua, Italy.; Department of Nutrition Sciences, University of Alabama at Birmingham, Birmingham, AL, USA.; Duke Clinical Research Institute, Duke University, Durham, NC, USA.; Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands.; Diabetes Trials Unit, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.; Clalit Health Services, Haifa, Israel.; Technion Faculty of Medicine, Haifa, Israel.; Department of Internal Medicine, Endocrinology, and Diabetology, Cardiometabolic Institute, Villingen-Schwenningen, Germany.; Cardiovascular Research Centre, School of Cardiovascular and Metabolic Health, British Heart Foundation, University of Glasgow, Glasgow, UK.; Peking University People's Hospital, Xicheng District, Beijing, China.; Renal Studies Group, Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.; Oxford Kidney Unit, Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 7LF, UK.; European Liver Patients' Association, Brussels, Belgium.; Faculty of Government and European Studies, New University, Kranj, Slovenia.; School of Life Course & Population Health Sciences, King's College London, London, WC2R 2LS, UK.; Department of Nursing, Cyprus University of Technology, Limassol, Cyprus.; Heart and Vascular Institute, Mass General Brigham, Harvard Medical School, Boston, MA, USA.; Division of Endocrinology and Diabetology, Medical University of Graz, Graz, Austria.; Kuratorium Für Heimdialyse Kidney Center, Munich, Germany.; Friedrich Alexander University of Erlangen, Erlangen, Germany.; Clinic for Cardiology, Angiology and Internal Intensive Care Medicine (Medical Clinic I), RWTH Aachen University Hospital, Aachen, Germany.; Department of Endocrinology, Catholic University of Leuven, Louvain, Belgium.; School of Cardiovascular and Metabolic Health, British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.; Diabetes Centre-Diabetic Foot Clinic, Second Department of Internal Medicine, Democritus University of Thrace, Alexandroupolis, Greece.; Division of Medicine, Department of Diabetes, University College London, Royal Free Campus, London, UK.; Department of Endocrinology and Metabolic Diseases, Charité Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany.; Deutsches Zentrum für Diabetesforschung E.V., Helmholtz Center Munich, Neuherberg, Germany.; Department of Diabetes and Endocrinology, Heart and Diabetes Center NRW, Faculty of Medicine, University Hospital, Ruhr-University Bochum, OWL University of Bielefeld, Bad Oeynhausen, Germany.; Endocrine and Metabolic Consultants, Rockville, MD, USA.; Department of Human Sciences and Promotion of Quality of Life, San Raffaele Open University of Rome, Rome, Italy.; IRCCS San Raffaele Roma, Rome, Italy.; Diacare-Diabetes Care and Hormone Clinic, Ahmedabad, India.; Department of Cardiovascular Medicine, Kawaguchi Cardiovascular and Respiratory Hospital, Kawaguchi, Japan.; Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.; Forschergruppe Diabetes E. V., Helmholtz Center Munich, Ingolstaedter Landstraße 1, 85764, Neuherberg, Germany.; Department of Hepatology and Gastroenterology, Charité Universitätsmedizin Berlin, Campus Virchow-Klinikum and Campus Charité Mitte, Berlin, Germany.; Department of Family Medicine, Acıbadem Mehmet Ali Aydınlar University School of Medicine, Istanbul, Turkey.; University Clinic of Würzburg, Würzburg, Germany.; University of Toronto, Toronto, Canada.; Wharton Weight Management Clinic, Toronto, Canada.; Sciarc GmbH, Baierbrunn, Germany.; Sciarc GmbH, Baierbrunn, Germany.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.